Search
Close this search box.

Nurix promotes O’Connor to CMO, Phiasivongsa to CTO

ARTICLE | Management Tracks

Plus: NodThera names Daniel Swisher CEO, and updates from Cogent, Sapreme and Biocom

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst

May 29, 2024 12:38 AM UTC

Protein modulation therapies company Nurix Therapeutics Inc. (NASDAQ:NRIX) promoted Paula O’Connor to CMO from EVP and head of clinical development, and Pasit Phiasivongsa to CTO from EVP of technical operations.

NodThera Ltd. named Daniel Swisher CEO, succeeding interim CEO Alan Watt, who will become president and CSO. Swisher was president and COO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)…